STOCKHOLM, SWEDEN--(Marketwire - May 06, 2010) - Swedish Orphan Biovitrum (STO: BVT) today
presents as a poster clinical phase II results from the first study showing
Kiobrina® added to infant formula significantly improve growth of
infants as compared to placebo after 1 week of treatment. The poster is
presented at "The Power of Programming 2010. International conference on
developmental origins of health and disease" in Munich, Germany.
Please find the poster enclosed.
"This is an interesting project and Kiobrina holds a great opportunity to
medical need in neonatal care. Based on these results and those from a
clinical phase II trial of Kiobrina in pasteurized mother's milk we are now
planning for a phase III study in preterm infants", said Peter Edman, CSO
Swedish Orphan Biovitrum.
Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL)
by Swedish Orphan Biovitrum, aiming to improve growth and development in
infants. The rationale for adding rhBSSL to pasteurized breast milk or
formula is to restore the natural lipase activity level that is either lost
pasteurization or totally absent in formula.
About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of
Orphan International Holding AB and created Swedish Orphan Biovitrum - a
company focused on treatment of rare diseases.
Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical
with an international market presence. The company is focused on providing
developing orphan and niche specialist pharmaceuticals to patients with
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipeline within rare diseases.
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
For more information please contact:
Swedish Orphan Biovitrum:
Peter Edman, CSO
Phone. +46 8 697 21 77
Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
Martin Nicklasson, CEO
Phone: +46 8 697 20 00
The clinical phase II studies have been carried out partially with research
funding from the European Community's Sixth Framework Program (The Early
Nutrition Programming Project, www.metabolic-programming.org). The press
release reflects only the author's views and does not necessarily reflect
the views of the European
Community or European Commission or their future policy, and they are
liable for any use that may be made of the information contained herein.
information in this document is provided as is and no guarantee or warranty
given that the information is fit for any particular purpose. The user
uses the information at its sole risk and liability.
Swedish Orphan Biovitrum may be required to disclose the information
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on May 6, 2010 at 8:30 a.m. CET.
Press release in PDF format:
Poster Kiobrina clinical phase II results: